Marlene & Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Leuk Res. 2013 Nov;37(11):1420-8. doi: 10.1016/j.leukres.2013.08.020. Epub 2013 Sep 7.
MicroRNAs (miRNAs) are small endogenous RNA molecules that regulate gene expression at the post-transcriptional level through its sequence complementation with target mRNAs. An individual miRNA species can simultaneously influence the expression of multiple genes and conversely, several miRNAs can synchronously control expression of specific gene product mRNA levels. Thus, miRNAs expression in cells has to be precisely regulated and alterations in miRNA levels may cause an aberrant expression of genes involved in oncogenic pathways and consequently result in cancer development. Indeed, miRNA expression is often deregulated in many cancers, including B-cell lymphomas. Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphomas with different genetic backgrounds, morphologic features, and responses to therapy. Over the past decade, miRNAs emerged as a new tool for understanding DLBCL biology, and promising candidate molecular markers in DLBCL classification and treatment. In this review, we will focus on miRNAs aberrantly expressed in DLBCL and discuss the putative mechanisms of this deregulation. Additionally, we will summarize miRNAs' involvement in the identification of DLBCL subgroups, and their potential role as diagnostic/prognostic biomarkers as well as specific therapeutic targets for DLBCL.
MicroRNAs (miRNAs) 是小的内源性 RNA 分子,通过与靶 mRNA 的序列互补,在转录后水平上调节基因表达。一种 miRNA 物种可以同时影响多个基因的表达,反之亦然,几个 miRNA 可以同步控制特定基因产物 mRNA 水平的表达。因此,细胞中 miRNA 的表达必须精确调控,miRNA 水平的改变可能导致癌基因通路中参与的基因异常表达,从而导致癌症的发生。事实上,许多癌症中 miRNA 的表达常常失调,包括 B 细胞淋巴瘤。弥漫性大 B 细胞淋巴瘤(DLBCL)是一组具有不同遗传背景、形态特征和治疗反应的 B 细胞淋巴瘤。在过去的十年中,miRNA 作为理解 DLBCL 生物学的新工具出现,并成为 DLBCL 分类和治疗中有前途的候选分子标志物。在这篇综述中,我们将重点讨论在 DLBCL 中异常表达的 miRNA,并讨论这种失调的潜在机制。此外,我们将总结 miRNA 参与 DLBCL 亚群的鉴定及其作为诊断/预后生物标志物以及 DLBCL 特定治疗靶点的潜在作用。